{"nctId":"NCT03875482","briefTitle":"A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis","startDateStruct":{"date":"2019-05-13","type":"ACTUAL"},"conditions":["Psoriasis"],"count":157,"armGroups":[{"label":"Risankizumab","type":"EXPERIMENTAL","interventionNames":["Drug: Risankizumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo solution for risankizumab"]}],"interventions":[{"name":"Risankizumab","otherNames":["ABBV-066","BI 655066"]},{"name":"Placebo solution for risankizumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant has diagnosis of chronic plaque psoriasis for at least 6 months before the baseline visit.\n* Participant meets following disease activity criteria:\n* Stable moderate to severe chronic plaque psoriasis, defined as greater than or equal to 10% body surface area (BSA) psoriasis involvement, static physician global assessment (sPGA) score of greater than or equal to 3, and Psoriasis Area Severity Index (PASI) greater than or equal to 12 at Screening and baseline visit.\n* Candidate for systemic therapy as assessed by the investigator.\n\nExclusion Criteria:\n\n* Participant has history of active skin disease other than psoriasis that could interfere with the assessment of psoriasis.\n* Participant has history of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis.\n* Participant has previous exposure to risankizumab.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 at Week 16","description":"The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \\* 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.9","spread":null},{"groupId":"OG001","value":"3.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear or Almost Clear at Week 16","description":"The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema, induration, and scaling of psoriatic lesions are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \\>0, \\<1.5; Mild (2) = mean ≥1.5, \\<2.5; Moderate (3) = mean ≥2.5, \\<3.5; and Severe (4) = mean ≥3.5.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.1","spread":null},{"groupId":"OG001","value":"9.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 100 at Week 16","description":"The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at Week 16) / PASI score at Baseline \\* 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.1","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear at Week 16","description":"The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema, induration, and scaling of psoriatic lesions are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean \\>0, \\<1.5; Mild (2) = mean ≥1.5, \\<2.5; Moderate (3) = mean ≥2.5, \\<3.5; and Severe (4) = mean ≥3.5.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.0","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Psoriasis Area Severity Index (PASI) Score up to Week 16","description":"The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked.The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. Negative values indicate an improvement from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-50.62","spread":null},{"groupId":"OG001","value":"-14.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-89.36","spread":null},{"groupId":"OG001","value":"-29.39","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":105},"commonTop":[]}}}